MX2022002961A - Metodos para tratar enfermedades neovasculares oculares usando variantes de aav2 que codifican para aflibercept. - Google Patents
Metodos para tratar enfermedades neovasculares oculares usando variantes de aav2 que codifican para aflibercept.Info
- Publication number
- MX2022002961A MX2022002961A MX2022002961A MX2022002961A MX2022002961A MX 2022002961 A MX2022002961 A MX 2022002961A MX 2022002961 A MX2022002961 A MX 2022002961A MX 2022002961 A MX2022002961 A MX 2022002961A MX 2022002961 A MX2022002961 A MX 2022002961A
- Authority
- MX
- Mexico
- Prior art keywords
- aav2
- amino acid
- methods
- ocular neovascular
- aflibercept
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962899070P | 2019-09-11 | 2019-09-11 | |
| US201962913648P | 2019-10-10 | 2019-10-10 | |
| PCT/US2019/062066 WO2021050094A1 (en) | 2019-09-11 | 2019-11-18 | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
| US202062959784P | 2020-01-10 | 2020-01-10 | |
| US202062971835P | 2020-02-07 | 2020-02-07 | |
| US202063019190P | 2020-05-01 | 2020-05-01 | |
| US202063030819P | 2020-05-27 | 2020-05-27 | |
| US202063063203P | 2020-08-07 | 2020-08-07 | |
| PCT/US2020/050079 WO2021050649A1 (en) | 2019-09-11 | 2020-09-10 | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022002961A true MX2022002961A (es) | 2022-04-06 |
Family
ID=72644941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022002961A MX2022002961A (es) | 2019-09-11 | 2020-09-10 | Metodos para tratar enfermedades neovasculares oculares usando variantes de aav2 que codifican para aflibercept. |
Country Status (18)
| Country | Link |
|---|---|
| EP (2) | EP4027983B1 (https=) |
| JP (2) | JP2022547541A (https=) |
| KR (1) | KR20220062353A (https=) |
| CN (1) | CN114375195A (https=) |
| AU (1) | AU2020345915A1 (https=) |
| BR (1) | BR112022004027A2 (https=) |
| CA (1) | CA3148376A1 (https=) |
| DK (1) | DK4027983T3 (https=) |
| ES (1) | ES3063491T3 (https=) |
| FI (1) | FI4027983T3 (https=) |
| HR (1) | HRP20260137T1 (https=) |
| IL (1) | IL291182A (https=) |
| LT (1) | LT4027983T (https=) |
| MX (1) | MX2022002961A (https=) |
| PT (1) | PT4027983T (https=) |
| RS (1) | RS67774B1 (https=) |
| SM (1) | SMT202600070T1 (https=) |
| WO (1) | WO2021050649A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118718181A (zh) | 2019-06-05 | 2024-10-01 | 里珍纳龙药品有限公司 | 用于精确剂量递送的装置及方法 |
| JP7842082B2 (ja) * | 2020-07-21 | 2026-04-07 | エフティージェン コーポレーション | 眼疾患を処置するための組成物および方法 |
| JP2024515459A (ja) | 2021-04-27 | 2024-04-10 | アドヴェラム バイオテクノロジーズ， インコーポレイテッド | アフリベルセプトをコードするａａｖ２バリアントを使用する眼疾患の治療方法 |
| MX2023014041A (es) * | 2021-05-28 | 2023-12-15 | Shanghai Regenelead Therapies Co Ltd | Virus adenoasociado recombinante que tiene una capsida variante y su aplicacion. |
| WO2023028457A1 (en) * | 2021-08-23 | 2023-03-02 | Duke University | Compositions for and methods of long-term integration of circuits using connexins |
| EP4479098A1 (en) * | 2022-02-16 | 2024-12-25 | Adverum Biotechnologies, Inc. | Method of reducing cst fluctuation in neovascular amd by a recombinant adeno-associated virus |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| WO2025026182A1 (zh) | 2023-08-01 | 2025-02-06 | 北京因诺惟康医药科技有限公司 | 融合多肽、包含其编码基因的表达盒、基因递送载体、药物组合物及用途 |
| KR20260004635A (ko) * | 2024-07-01 | 2026-01-09 | 삼성바이오에피스 주식회사 | 애플리버셉트를 암호화하는 코돈-최적화된 폴리뉴클레오티드를 포함하는 발현 카세트 및 이를 포함하는 rAAV 생산용 플라스미드 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2544136B2 (ja) * | 1986-05-23 | 1996-10-16 | 第一製薬株式会社 | 硫酸化多糖体ｄｓ４１５２を含有する血管新生抑制剤及び抗腫瘍剤 |
| TW201105363A (en) * | 2009-07-14 | 2011-02-16 | Univ Yamagata | Eye drop for macular edema treatment |
| HRP20171334T1 (hr) | 2011-04-22 | 2017-11-17 | The Regents Of The University Of California | Virioni adeno-povezanog virusa s kapsid varijantom i postupci njihove upotrebe |
| AU2014252808A1 (en) * | 2013-04-09 | 2015-11-12 | Cresset Biomolecular Discovery Ltd | The treatment of inflammatory disorders |
| DK3471780T3 (da) * | 2016-06-16 | 2020-11-23 | Adverum Biotechnologies Inc | Behandling af amd med aav2-variant med aflibercept |
| CN110546257B (zh) | 2017-03-17 | 2024-03-01 | 阿德夫拉姆生物技术股份有限公司 | 用于增强基因表达的组合物和方法 |
-
2020
- 2020-09-10 FI FIEP20780467.5T patent/FI4027983T3/fi active
- 2020-09-10 KR KR1020227011745A patent/KR20220062353A/ko active Pending
- 2020-09-10 AU AU2020345915A patent/AU2020345915A1/en active Pending
- 2020-09-10 DK DK20780467.5T patent/DK4027983T3/da active
- 2020-09-10 PT PT207804675T patent/PT4027983T/pt unknown
- 2020-09-10 RS RS20260196A patent/RS67774B1/sr unknown
- 2020-09-10 LT LTEPPCT/US2020/050079T patent/LT4027983T/lt unknown
- 2020-09-10 JP JP2022515692A patent/JP2022547541A/ja not_active Withdrawn
- 2020-09-10 MX MX2022002961A patent/MX2022002961A/es unknown
- 2020-09-10 SM SM20260070T patent/SMT202600070T1/it unknown
- 2020-09-10 WO PCT/US2020/050079 patent/WO2021050649A1/en not_active Ceased
- 2020-09-10 EP EP20780467.5A patent/EP4027983B1/en active Active
- 2020-09-10 BR BR112022004027A patent/BR112022004027A2/pt unknown
- 2020-09-10 ES ES20780467T patent/ES3063491T3/es active Active
- 2020-09-10 CA CA3148376A patent/CA3148376A1/en active Pending
- 2020-09-10 CN CN202080063266.4A patent/CN114375195A/zh active Pending
- 2020-09-10 EP EP25180005.8A patent/EP4696318A1/en active Pending
- 2020-09-10 HR HRP20260137TT patent/HRP20260137T1/hr unknown
-
2022
- 2022-03-08 IL IL291182A patent/IL291182A/en unknown
-
2025
- 2025-05-07 JP JP2025077233A patent/JP2025118798A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FI4027983T3 (fi) | 2026-02-03 |
| EP4027983A1 (en) | 2022-07-20 |
| WO2021050649A1 (en) | 2021-03-18 |
| EP4027983B1 (en) | 2025-11-19 |
| RS67774B1 (sr) | 2026-03-31 |
| BR112022004027A2 (pt) | 2022-05-31 |
| CN114375195A (zh) | 2022-04-19 |
| AU2020345915A1 (en) | 2022-03-24 |
| SMT202600070T1 (it) | 2026-03-09 |
| CA3148376A1 (en) | 2021-03-18 |
| EP4696318A1 (en) | 2026-02-18 |
| DK4027983T3 (da) | 2026-02-09 |
| JP2022547541A (ja) | 2022-11-14 |
| HRP20260137T1 (hr) | 2026-03-13 |
| IL291182A (en) | 2022-05-01 |
| LT4027983T (lt) | 2026-02-25 |
| JP2025118798A (ja) | 2025-08-13 |
| PT4027983T (pt) | 2026-02-25 |
| KR20220062353A (ko) | 2022-05-16 |
| ES3063491T3 (en) | 2026-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022002961A (es) | Metodos para tratar enfermedades neovasculares oculares usando variantes de aav2 que codifican para aflibercept. | |
| MX2024009478A (es) | Métodos para tratar enfermedades neovasculares oculares con variantes de aav2 que codifican aflibercept | |
| PH12020550094A1 (en) | Adeno-associated virus variant capsids and methods of use thereof | |
| UY38881A (es) | Métodos de tratamiento de enfermedades neovasculares oculares utilizando variantes de aav2 que codifican aflibercept | |
| MX2023012410A (es) | Metodos para tratar enfermedades oculares usando variantes de aav2 que codifican aflibercept. | |
| PH12018502387A1 (en) | Adeno-associated virus variant capsids and methods of use thereof | |
| CL2020001360A1 (es) | Cápsides variantes de virus adenoasociados y su uso para inhibir la angiogénesis. | |
| MX2021011468A (es) | Vectores de virus adenoasociados recombinantes. | |
| CL2019002474A1 (es) | Vector clado f de virus adeno-asociado (vaa) y usos relacionados. | |
| MX2020008932A (es) | Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidacion reducida de la capside y usos de estos. | |
| AR124119A2 (es) | Partículas virales modificadas y usos de estas | |
| JP2017518271A5 (https=) | ||
| MX2023006694A (es) | Tratamiento de la enfermedad de danon. | |
| CO2022015313A2 (es) | Variantes de cápsides de aav y usos de los mismos | |
| MX2023002695A (es) | Virus adeno-asociado para la administración de kh902 (conbercept) y usos del mismo. | |
| MX2024010002A (es) | Metodo para reducir la fluctuacion del cst en amd neovascular mediante un virus adenoasociado recombinante | |
| MX2022002960A (es) | Metodos para tratar enfermedades neovasculares oculares usando variantes de aav2 que codifican para aflibercept. | |
| AR133185A1 (es) | Métodos para tratar enfermedades neovasculares oculares usando variantes de aav2 que codifican aflibercept | |
| AR119955A1 (es) | Métodos de tratamiento de enfermedades neovasculares oculares utilizando variantes de aav2 que codifican aflibercept | |
| WO2025010334A3 (en) | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept | |
| PE20241336A1 (es) | Proteina de la capside vp1 modificada aislada del virus adenoasociado de serotipo 9 (aav9), capside y vector basado en la misma | |
| MY186651A (en) | Adeno-associated virus variant capsids and methods of use thereof | |
| AR128450A1 (es) | Vectores de virus adeno-asociados recombinantes, y métodos de uso de los mismos | |
| NZ749467A (en) | Novel adeno-associated virus capsid proteins | |
| TH1801006923A (th) | แคปซิดของไวรัสที่เกี่ยวข้องกับอะดีโนชนิดแวเรียนต์และวิธีการใช้มัน |